Navigation Links
Novira Therapeutics Completes $25 Million Series A Financing

DOYLESTOWN, Pa., March 25, 2013 /PRNewswire/ -- Novira Therapeutics, Inc. today announced the completion of its Series A financing after securing $7.5 million from new investor Versant Ventures. This brings the total raised from all investors in the round to $25 million. Versant joins 5AM Ventures and Canaan Partners, which led the first closing of the Series A in August 2012. In conjunction with this investment, Gianni Gromo M.D ., Ph.D., venture partner with Versant Ventures, joined the company's board of directors.

"We believe the addition of Versant bolsters an already strong investor syndicate," said Osvaldo Flores , Ph.D., president and chief scientific officer of Novira. "We also welcome Gianni to our board and believe his extensive industry experience will contribute greatly to our future success. We plan to use these funds to advance development of our hepatitis B virus (HBV) capsid inhibitor lead program toward the clinic and to discover additional HBV drug candidates."

Dr. Gromo added, "Novira's innovative HBV capsid inhibitor program and the company's highly experienced management team made this an attractive investment for Versant. We believe that Novira's approach to HBV capsid inhibition may disrupt pathways involved in virus persistence and has the potential to produce treatments that can cure millions of patients worldwide who are living with chronic HBV infection."

About Hepatitis B

More than 2 billion people worldwide have been infected with HBV at some time in their lives. Adults with a healthy immune system are capable of clearing HBV infection, but newborns, young children and immunocompromised patients frequently become chronically infected. Approximately 400 million people worldwide suffer from chronic HBV infection, with a significant percentage of those individuals dying from long-term complications such as liver cirrhosis or liver cancer. Treatment with nucleotide/nucleoside analogs can effectively suppress viral replication and delay progression of liver disease but does do not typically lead to a sustained virologic response or cure.

About Versant Ventures

Versant Ventures is a leading venture capital firm that specializes in investments in innovative biopharmaceuticals, medical devices and other life science opportunities. Founded in 1999, the firm consists of an experienced team of managing directors committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. The firm's successful IPOs include Clovis Oncology, Jazz Pharmaceuticals, Genomic Health, Insulet and Kythera. M&A exits include Amira, LenSX, Acclarent, Cameron Health Ablation Frontiers and Lutonix. In addition to an industry-leading biotech-focused team in Basel, Switzerland and the San Francisco Bay Area, Versant has a presence in two other key geographic locations of Southern California and Minnesota.

For more information visit

About Novira Therapeutics

Novira Therapeutics, Inc. is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV infection, a global disease with a high level of unmet medical need. Novira's oral drugs target the capsid of the virus and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company's antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors is rarely curative despite lifelong treatment. Capsid inhibitors that feature a new mechanism of action may address the limitations in the effectiveness of HBV therapy.

For more information, visit


Corporate Contact
Osvaldo Flores , Ph.D.
President, CSO

Media Contacts
David Schull                           
Matt Middleman, M.D.                                   
Russo Partners                                              
T: 212-845-4271                                
T: 212-845-4272

SOURCE Novira Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
3. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
4. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
5. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
6. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
7. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
8. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
9. United Therapeutics Announces Additional $420 Million Share Repurchase Program
10. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
11. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
Post Your Comments:
(Date:10/7/2015)... , October 8, 2015 ... Medical biotechnology accounts for largest bioinformatics market ... in drug discovery and development process says ... . --> ... the basis of applications, the bioinformatics market ...
(Date:10/7/2015)... , ... October 07, 2015 , ... ... ) will present a public educational seminar on the latest advances in ... 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square ...
(Date:10/7/2015)...   PDI , a leader in infection prevention ... key challenges across various healthcare settings, as well as ... This tool is part of a larger effort to ... efficiencies and lower healthcare-associated infections. ... of how to use the right product, in the ...
(Date:10/7/2015)... , Oct. 7, 2015   Intrexon Corporation ... today announced it will hold an Investor Day in ... afternoon of Thursday, November 12, 2015. Intrexon,s Chairman and ... other members of the Company,s management team as well ... focus on strategic initiatives, product pipeline, and program updates ...
Breaking Biology Technology:
... (Amex: PLX ), announced today that it ... its manufacturing and research,facility. The expanded space, located ... the Company with approximately three times its current,manufacturing ... Company,s lead product candidate, prGCD, a therapeutic protein ...
... The Woodbridge Group announced,the most extensive interior ... "Green" Polyurethane Foams. As a key component ... technology, substitutes petroleum,with plant oils, in the ... a full line-up of automotive interior,applications includes; ...
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patent listed by Forest,Laboratories, Inc. in ... 10mg., Barr filed its Abbreviated New Drug ... generic Namenda product with the U.S. Food,& Drug ...
Cached Biology Technology:
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. ... interface solutions, today announced that Lenovo has selected Synaptics ... sensor, FS4202, for its latest smartphone, the Vibe P1. ... access to unlock the device and provide swift access ... The feature-rich Natural ID FS4202 sensor solution utilizes ...
(Date:9/24/2015)... 2015  EyeLock LLC, a market leader of iris-based ... and latest technology in Booth #602 at next week,s ... EyeLock,s iris authentication technology provides an unprecedented ... making it the most proven way to authenticate one,s ... to deliver a fast and friendly user experience to ...
(Date:9/10/2015)... This report provides detailed descriptions of the ... emerging sensor types that will dominate in the future. ... the wearable technology hype curve in the last five ... feature with all of them is the prominence of ... useful functions. Sensors collect data about the physical and ...
Breaking Biology News(10 mins):
... Amsterdam, 16 March, 2011 A recent special edition ... Elsevier, on behalf of the British Mycological Society, features a ... collection of fungal cell biology movies ever published. The movies ... Exeter, UK, who is a renowned researcher in the field ...
... analyze the complex ingredients in the new genre of ... for cigarettes in places where smoking is banned have ... The report appears in ACS,s Journal of Agricultural ... colleagues point out that the first dissolvable tobacco products ...
... Trends in Plant Science , provides an overview ... for ecologists, physiologists and molecular biologists, since it covers ... change. The results show that plants in ... to a changing environment without requiring any evolutionary changes, ...
Cached Biology News:
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... Since OligoEngine introduced the industry's first ... have constantly strived to keep these tools ... research reports in the field of RNAi. ... enhanced, and expanded RNAi design tools, OligoEngine ...
... for enzyme-/substrate-based blotting what intensifying screens do for ... to 10-fold (or one order of magnitude) in ... Enhancer membrane treatment is a simple, 15-minute procedure ... Western blotting protocol. The result is an increase ...
Biology Products: